Preexisting MEK1 Exon 3 Mutations in (V600E/K)BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with advanced (V600E/K)BRAF melanomas. Somatic activating MEK1 mutations are thought to be rare in melanomas, but their potential concurrence with (V600E/K)BRAF may be selected for by BRAFi. We sequenced MEK1/2 exon 3 in me...

詳細記述

保存先:
書誌詳細
主要な著者: Shi, Hubing, Moriceau, Gatien, Kong, Xiangju, Koya, Richard C., Nazarian, Ramin, Pupo, Gulietta M., Bacchiocchi, Antonella, Dahlman, Kimberly B., Chmielowski, Bartosz, Sosman, Jeffrey A., Halaban, Ruth, Kefford, Richard F., Long, Georgina V., Ribas, Antoni, Lo, Roger S.
フォーマット: Artigo
言語:Inglês
出版事項: 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594852/
https://ncbi.nlm.nih.gov/pubmed/22588879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0022
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料